PHAXIAM Therapeutics S.A. (0QSS.L)
EUR 1.76
(1.03%)
EUR 1.76
(1.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -22.93 Million EUR | 32.65% |
| 2022 | 3.07 Million EUR | 47.26% |
| 2021 | -52.48 Million EUR | 18.12% |
| 2020 | -69.41 Million EUR | -3.71% |
| 2019 | -60.82 Million EUR | -37.8% |
| 2018 | -41.77 Million EUR | -40.17% |
| 2017 | -33 Million EUR | -30.79% |
| 2016 | -24.9 Million EUR | -42.12% |
| 2015 | -16.88 Million EUR | -109.24% |
| 2014 | -8.67 Million EUR | -26.51% |
| 2013 | -6.85 Million EUR | -689.97% |
| 2012 | -1.58 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.27 Million EUR | -221.63% |
| 2024 Q2 | -5.27 Million EUR | 0.0% |
| 2023 Q2 | -12.41 Million EUR | -214.4% |
| 2023 FY | - EUR | 18.39% |
| 2023 Q3 | -8.62 Million EUR | 30.51% |
| 2023 Q4 | -1.64 Million EUR | 80.97% |
| 2023 Q1 | -3.94 Million EUR | 42.9% |
| 2022 Q3 | -4.7 Million EUR | 77.52% |
| 2022 FY | - EUR | 47.26% |
| 2022 Q4 | -6.91 Million EUR | -47.08% |
| 2022 Q2 | -20.92 Million EUR | -79.56% |
| 2022 Q1 | -11.65 Million EUR | 56.16% |
| 2021 Q3 | -13.73 Million EUR | 52.2% |
| 2021 FY | - EUR | 18.12% |
| 2021 Q4 | -26.57 Million EUR | -93.44% |
| 2021 Q1 | -12.38 Million EUR | 62.31% |
| 2021 Q2 | -28.74 Million EUR | -132.16% |
| 2020 Q4 | -32.85 Million EUR | -109.51% |
| 2020 FY | - EUR | -3.71% |
| 2020 Q1 | -18.64 Million EUR | 43.55% |
| 2020 Q2 | -34.78 Million EUR | -86.57% |
| 2020 Q3 | -15.67 Million EUR | 54.92% |
| 2019 Q1 | -13.07 Million EUR | -32.96% |
| 2019 Q2 | -32.11 Million EUR | -145.66% |
| 2019 FY | - EUR | -37.8% |
| 2019 Q4 | -33.02 Million EUR | -105.3% |
| 2019 Q3 | -16.08 Million EUR | 49.91% |
| 2018 Q4 | -9.83 Million EUR | 15.29% |
| 2018 Q3 | -11.6 Million EUR | 6.32% |
| 2018 Q2 | -12.39 Million EUR | -35.65% |
| 2018 Q1 | -9.13 Million EUR | 5.69% |
| 2018 FY | - EUR | -40.17% |
| 2017 Q4 | -9.68 Million EUR | -42.63% |
| 2017 Q1 | -6.42 Million EUR | -11.11% |
| 2017 Q2 | -7.53 Million EUR | -17.23% |
| 2017 FY | - EUR | -30.79% |
| 2017 Q3 | -6.79 Million EUR | 9.84% |
| 2016 Q2 | -6.09 Million EUR | -40.02% |
| 2016 Q4 | -5.78 Million EUR | -0.03% |
| 2016 Q3 | -5.78 Million EUR | 5.21% |
| 2016 FY | - EUR | -42.12% |
| 2016 Q1 | -4.35 Million EUR | -1.28% |
| 2015 Q4 | -4.3 Million EUR | -0.42% |
| 2015 Q3 | -4.28 Million EUR | -27.23% |
| 2015 FY | - EUR | -109.24% |
| 2015 Q2 | -3.36 Million EUR | 0.0% |
| 2015 Q1 | -3.36 Million EUR | -20.16% |
| 2014 Q4 | -2.8 Million EUR | 0.0% |
| 2014 Q1 | -1.53 Million EUR | 23.9% |
| 2014 Q3 | -2.8 Million EUR | -82.49% |
| 2014 Q2 | -1.53 Million EUR | 0.0% |
| 2014 FY | - EUR | -26.51% |
| 2013 FY | - EUR | -689.97% |
| 2013 Q2 | -1.41 Million EUR | 0.0% |
| 2013 Q3 | -2.01 Million EUR | -43.01% |
| 2013 Q1 | -1.41 Million EUR | -238.71% |
| 2013 Q4 | -2.01 Million EUR | 0.0% |
| 2012 Q4 | 1.01 Million EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Boiron SA | 80.67 Million EUR | 128.421% |
| Laboratorios Farmaceuticos Rovi, S.A. | 238.01 Million EUR | 109.634% |
| Vetoquinol SA | 104.58 Million EUR | 121.926% |
| Valneva SE | -64.51 Million EUR | 64.459% |
| AB Science S.A. | -9.28 Million EUR | -147.064% |
| Nanobiotix S.A. | -34.01 Million EUR | 32.596% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 19.127% |
| BioSenic S.A. | -6.79 Million EUR | -237.404% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 82.786% |
| Formycon AG | 81.05 Million EUR | 128.29% |